Steven R. Feldman, MD, PhD, professor of dermatology, Wake Forest School of Medicine, discusses how some drugs for psoriasis are less effective in the presence of metabolic syndrome.
Steven R. Feldman, MD, PhD, professor of dermatology, Wake Forest School of Medicine, discusses how some drugs for psoriasis are less effective in the presence of metabolic syndrome.
TranscriptHow does the presence of metabolic syndrome impact the efficacy of psoriasis treatment?
The presence of metabolic syndrome does affect the efficacy of psoriasis treatments, or at least it’s associated with worse efficacy. So, there was a study done that found people with metabolic syndrome had high rates of failing their treatment for their psoriasis. It may help to use medicines that are either more potent or don’t care whether you have metabolic syndrome.
Are there any data to help clinicians select an effective psoriasis treatment for patients who also have metabolic syndrome?
There are some data that tell us what drug might be more effective for someone with metabolic syndrome. Some of the drugs are dosed based on weight. And for those drugs, the heavier patients do well on a higher dose—and we have the data to support that. Other drugs may not be weight based, and they may have some tendency to be less effective in people who are more obese. One of the drugs, tildrakizumab, had some data showing it worked equally well in patients who either had or did not have metabolic syndrome.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Brodalumab Is Effective, Safe in Patients With Moderate to Severe Psoriasis
March 18th 2024Posters presented at the American Academy of Dermatology Annual Meeting demonstrated both short- and long-term efficacy and safety profiles of brodalumab in patients with moderate to severe psoriasis.
Read More
Quality of Life, Severity Scales Correlated in Patients With Psoriasis Worldwide
March 13th 2024Study findings show that scores on the Psoriasis Area and Severity Index and the Dermatology Quality of Life Index are correlated in patients with psoriasis across several continents, but factors affecting each of these scores are different across countries.
Read More